Bridge City Capital LLC Increases Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Bridge City Capital LLC lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 65.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 115,855 shares of the company's stock after acquiring an additional 45,760 shares during the quarter. Bridge City Capital LLC owned approximately 0.24% of Amphastar Pharmaceuticals worth $3,359,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of AMPH. Dimensional Fund Advisors LP boosted its stake in Amphastar Pharmaceuticals by 9.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock valued at $44,503,000 after buying an additional 105,288 shares during the period. Northern Trust Corp increased its stake in Amphastar Pharmaceuticals by 5.1% during the 4th quarter. Northern Trust Corp now owns 613,170 shares of the company's stock valued at $22,767,000 after purchasing an additional 29,808 shares in the last quarter. Marshall Wace LLP increased its holdings in Amphastar Pharmaceuticals by 7.1% in the 4th quarter. Marshall Wace LLP now owns 608,706 shares of the company's stock worth $22,601,000 after buying an additional 40,212 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Amphastar Pharmaceuticals by 7.4% in the fourth quarter. Renaissance Technologies LLC now owns 525,500 shares of the company's stock worth $19,512,000 after acquiring an additional 36,100 shares during the period. Finally, Bessemer Group Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 2.4% during the 4th quarter. Bessemer Group Inc. now owns 488,630 shares of the company's stock worth $18,144,000 after acquiring an additional 11,609 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Up 1.8%

Shares of Amphastar Pharmaceuticals stock opened at $25.99 on Monday. Amphastar Pharmaceuticals, Inc. has a 52-week low of $22.64 and a 52-week high of $53.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $1.23 billion, a P/E ratio of 8.66, a P/E/G ratio of 2.19 and a beta of 0.77. The company has a 50 day moving average of $24.64 and a 200 day moving average of $31.42.

Analysts Set New Price Targets

Several analysts recently issued reports on AMPH shares. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Finally, Wells Fargo & Company lowered their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $32.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.